Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 8 de 8
Filtrer
1.
Genet Mol Res ; 15(3)2016 Aug 30.
Article de Anglais | MEDLINE | ID: mdl-27706674

RÉSUMÉ

Thyroid orbitopathy (TO) is an autoimmune disease that is complicated by ocular surface disorders, leading to discomfort. Dry eye is very prevalent in patients with TO. Recent studies on the pathogenesis of dry eye have focused on the inflammatory process, and some supporting evidence has been discovered. Because TO is a disorder of autoimmune origin, we assumed that the association between TO and dry eye is related to inflammation. Inflammation of the ocular surface in TO-related dry eye has not been well studied. In this study, we assessed cellular inflammation of the ocular surface and the cytokine profiles in patients with TO-related dry eye. Conjunctival impression cytology (CIC) was assessed with an immunofluorescent assay. TO-related dry eye was diagnosed by using the Schirmer test, tear break-up time, thyroid function, and clinical signs. CIC was combined with immunological staining of interleukin-1a (IL-1a), IL-1b, and IL- 6. The immunological impression cytology (IC) grade was compared to the clinical activity score of TO. All TO patients with dry eye were positive for IL-1a, IL-1b, and IL-6. However, the normal controls were also positive for IL-1a. A trend was observed between the clinical inflammatory score and immunological IC grade. This study was the first to delineate the immunological IC of TO-related dry eye. Our study aimed to investigate the pathogenesis of dry eye in TO. Our findings suggest that the conjunctival cytokines IL-1a, IL-1b, and IL-6 may play a role. The results of this study will be useful for future studies of additional inflammatory cytokines, and the levels of these cytokines could be used as an outcome to assess the efficacy of treatment, such as anti-cytokine or immunosuppression therapy, in patients with TO-related dry eye or other ocular surface inflammatory disorders.


Sujet(s)
Maladies auto-immunes/diagnostic , Conjonctive/anatomopathologie , Syndromes de l'oeil sec/diagnostic , Maladies de la thyroïde/diagnostic , Adolescent , Adulte , Sujet âgé , Maladies auto-immunes/immunologie , Maladies auto-immunes/métabolisme , Études cas-témoins , Conjonctive/métabolisme , Techniques cytologiques , Syndromes de l'oeil sec/immunologie , Syndromes de l'oeil sec/métabolisme , Épithélium/métabolisme , Épithélium/anatomopathologie , Femelle , Humains , Techniques immunologiques , Médiateurs de l'inflammation/métabolisme , Mâle , Adulte d'âge moyen , Maladies de la thyroïde/immunologie , Maladies de la thyroïde/métabolisme , Jeune adulte
4.
NCI Monogr ; (6): 279-84, 1988.
Article de Anglais | MEDLINE | ID: mdl-3281031

RÉSUMÉ

The Radiation Therapy Oncology Group (RTOG) and the Eastern Cooperative Oncology Group (ECOG) conducted a phase III trial in patients with malignant gliomas to evaluate 4 treatment arms: 1) 60 Gy to the whole brain; 2) 60 Gy plus 10-Gy boost; 3) 60 Gy plus carmustine (BCNU); and 4) 60 Gy plus semustine plus dacarbazine. Between September 1974 and March 1979, 626 patients with malignant gliomas were treated on protocol RTOG 7401/ECOG 1374. Each institution chose a subset of the treatments to which the patients would be randomized. Patients were stratified according to subset and randomized to the 4 treatment arms. There were no differences in survival among treatment arms. For patients greater than 60 years of age, the addition of chemotherapy to radiation therapy did not improve survival. For patients aged 40-60 years, there was a statistically significant increase in overall survival when BCNU was added to 60 Gy (P less than .01), with an increase in 2-year survival from 8% to 23%. This beneficial effect of BCNU is apparent in both histological groups (astrocytoma with atypical or anaplastic foci and glioblastoma multiforme). Although few confirmatory autopsies are available, long-term survival in patients with astrocytomas with atypical and anaplastic foci who were treated with 60 Gy plus BCNU (5-yr survival, 22%) suggests no significant late CNS toxicity, compared to 60 Gy alone (5-yr survival, 15%). This is confirmed by comparable neurological function in long-term survivors.


Sujet(s)
Tumeurs du cerveau/thérapie , Gliome/thérapie , Adulte , Facteurs âges , Tumeurs du cerveau/mortalité , Carmustine/effets indésirables , Carmustine/usage thérapeutique , Essais cliniques comme sujet , Association thérapeutique , Études de suivi , Gliome/mortalité , Humains , Adulte d'âge moyen , Dosimétrie en radiothérapie/effets indésirables
6.
J Pediatr ; 90(3): 361-7, 1977 Mar.
Article de Anglais | MEDLINE | ID: mdl-402457

RÉSUMÉ

Liver biopsy was performed to exclude anatomic obstruction of the biliary tract in five prematurely born infants who had developed conjugated hyperbilirubinemia during intravenous alimentation with a protein hydrolysate. Each was being treated after having undergone a segmental intestinal resection for necrotizing enterocolitis. Bacterial and viral infections, metabolic disorders, and isoimmune hemolytic disease were excluded as possible causes of jaundice. Light microscopic and ultrastructural analysis disclosed cholestasis and hepatocellular injury without significant inflammatory reaction. Jaundice abated following permanent discontinuation of parenteral alimentation. The jaundice and cholestasis are interpreted to be hepatotoxic effects because of (1) their temporal relationship to the treatment and (2) the presence of hepatocellular damage.


Sujet(s)
Hyperbilirubinémie/induit chimiquement , Maladies du prématuré/induit chimiquement , Nutrition parentérale totale , Nutrition parentérale , Hydrolysats de protéines/effets indésirables , Ponction-biopsie à l'aiguille , Cholestase/anatomopathologie , Humains , Nouveau-né , Foie/anatomopathologie , Nutrition parentérale/effets indésirables , Nutrition parentérale totale/effets indésirables , Hydrolysats de protéines/administration et posologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE